Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Preventive Healthcare Services

Preventive Healthcare Services

Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

HPV self-sampling and follow-up over two rounds of cervical screening in Australia - the iPap trial.

Journal of medical screening·2022

Same author

Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.

Gynecologic oncology·2019

Same author

Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

BMJ open·2018

Same author

HAVE YOU HAD THE HPV VACCINE? YOU STILL NEED TO BE SCREENED FOR CERVICAL CANCER.

Australian nursing & midwifery journal·2017

Same author

Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.

PLoS medicine·2017

Same author

Home-based HPV self-sampling improves participation by never-screened and under-screened women: Results from a large randomized trial (iPap) in Australia.

International journal of cancer·2016

Search research articles

Related Experiment Video

Updated: May 10, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

HPV testing in the National Cervical Screening Program--when is it recommended?

¹Victorian Cytology Service, Melbourne, Victoria, Australia. sheley@vcs.org.au

Australian Family Physician

|July 5, 2013

Summary

Human papillomavirus (HPV) testing is recommended after treatment for high-grade cervical squamous intraepithelial lesions (HSILs). Appropriate HPV testing allows many women to safely return to routine cervical screening intervals.

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Related Experiment Videos

Last Updated: May 10, 2026

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Area of Science:

Gynecology
Oncology
Virology

Background:

Traditionally, women with high-grade cervical squamous intraepithelial lesions (HSILs) underwent annual cervical smears post-treatment.
Current guidelines, updated in 2005, integrate high-risk human papillomavirus (HPV) testing into follow-up care for these patients.
A gap exists, with healthcare providers not consistently performing HPV tests on eligible women.

Purpose of the Study:

To emphasize the importance of HPV testing following HSIL treatment.
To inform clinicians about the role of HPV testing in risk assessment and guiding return to routine screening.

Main Methods:

The study highlights the established protocol for post-treatment surveillance of HSIL.
It emphasizes the use of concurrent cervical cytology and high-risk HPV testing.

Main Results:

Persistent high-risk HPV infections are a primary cause of HSIL, potentially progressing to cervical cancer.
Most HSIL cases regress after treatment, but ongoing risk assessment is crucial.
HPV testing effectively identifies persistent infections and guides management decisions.

Conclusions:

Cervical cytology combined with HPV testing should begin 12 months post-treatment and continue annually.
Women testing negative for both cytology and HPV on two consecutive occasions can safely revert to routine 2-yearly Pap screening.
This approach ensures appropriate monitoring and reduces unnecessary interventions.